PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Frontiers in Pharmacology2 citationsOpen Access

Molecular features of prenylated (iso)flavonoids from Fabaceae in relation to their potential NorA inhibition in Staphylococcus aureus

View Full Paper
MIMarina Ika IriantiJRJanniek Henrieke RitsemaJHJos Hageman

Key Points

  • The study aims to explore molecular properties of prenylated (iso)flavonoids from Fabaceae as potential inhibitors of the NorA efflux pump in Staphylococcus aureus.
  • Evaluated 37 prenylated (iso)flavonoids against norA-overexpressing Staphylococcus aureus using checkerboard and ethidium accumulation assays.
  • Utilized a norA-knockout strain to confirm the specificity of the effects observed.
  • Developed in silico binary QSAR and pharmacophore models to identify key molecular features for NorA inhibition.
  • Seven prenylated (iso)flavonoids significantly potentiated ciprofloxacin and erythromycin activity in norA-overexpressing strains.
  • Potentiation of ciprofloxacin was up to 8-fold at 10 μM without membrane permeabilization effects.
  • Developed QSAR models achieved prediction accuracies of up to 90% for active compounds, correlating specific molecular characteristics with antibiotic potentiation.

Abstract

Background The overexpression of the NorA efflux pump is known to be an important factor in the antimicrobial resistance mechanism of Staphylococcus aureus . Therefore, NorA inhibition can help disarm this pathogen and tackle antimicrobial resistance. In this study, we aim to unravel the molecular properties of prenylated (iso)flavonoids from Fabaceae as potential NorA inhibitors and to propose leading compounds for future research. Methods A collection of 37 prenylated isoflavonoids and flavonoids (obtained by purification, chemically synthesized, or commercially purchased), collectively referred to as (iso)flavonoids, was evaluated for its activity against norA -overexpressing Staphylococcus aureus using the checkerboard assay with ciprofloxacin (NorA substrate) and erythromycin (primarily non-NorA substrate), in combination with ethidium accumulation assays. Moreover, a norA -knockout Staphylococcus aureus strain was used to corroborate the specificity of the observed effects. Subsequently, in silico binary QSAR and pharmacophore models were developed to elucidate the key molecular properties for potential NorA inhibition. Results Seven prenylated (iso)flavonoids, namely, 8-prenylnaringenin, 6- C ,7- O -diprenylnaringenin, glabrene, neobavaisoflavone, wighteone, licoisoflavone A, and glycyrrhisoflavone, potentiated ciprofloxacin up to 8-fold in norA- overexpressing and up to 2-fold in norA- knockout strains at 10 μM, without any membrane permeabilization effects. Moreover, prenylated (iso)flavonoids potentiated erythromycin in norA- overexpressing Staphylococcus aureus only up to 2-fold. Binary QSAR models were generated using datasets from the checkerboard and ethidium accumulation assays with a total prediction accuracy of up to 90% for active and 88% for inactive compounds. Based on QSAR models, the polar surface area, the balance of hydrophobicity and hydrophilicity, and the overall hydrophobicity were correlated with antibiotic potentiation and efflux inhibition of prenylated (iso)flavonoids. Moreover, in our study, we revealed that fractional negative polar surface area and formal (negative) charges are key properties that differentiate prenylated (iso)flavonoids with antimicrobial activity from those that act as potential NorA inhibitors. A pharmacophore model provided the basis for further optimization of prenylated (iso)flavonoids, mainly neobavaisoflavone and wighteone, as potential NorA inhibitors. Conclusion In our study, we provide, for the first time, predictive QSAR models of prenylated (iso)flavonoids as potential NorA inhibitors and propose two potential leads based on this family of plant-derived compounds. Future research on the specificity and validation of prenylated (iso)flavonoids as NorA inhibitors is required.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Irianti et al. (2026) studied this question.

synapsesocial.com/papers/6980fe13c1c9540dea80fdfbhttps://doi.org/10.3389/fphar.2025.1715533
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1197 NorA efflux pump inhibition in S. aureus using novel lead compounds in a DiOC3 real-time efflux assay2024
  2. 2Synthesis and in Silico Pharmacokinetics of Some Sulfone Functionalized Thioproline Appended α/γ Hybrid Peptides as Potential Inhibitors of NorA Efflux Pump in <i>Staphylococcus aureus</i>2026
  3. 3Synthesis, Characterization, and Computational Insights of Flavone Derivatives as Promising Antimicrobial Agents2025
  4. 4Unraveling the ligand specificity and promiscuity of the <i>Staphylococcus aureus</i> NorA efflux pump: a computational study2024 · 2 citations
  5. 5Mechanistic insight into the mode of inhibition of dietary flavonoids; targeting macrophage migration inhibitory factor2024 · 3 citations